Table 3 Study drug-related treatment-emergent adverse events in ≥10% of the safety population
From: A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Preferred Term, n (%) | LY2603618/gemcitabine | Gemcitabine |
|---|---|---|
(n = 65) | (n = 34) | |
Patients with ≥1 TEAE | 58 (89.2) | 31 (91.2) |
Thrombocytopenia | 21 (32.3) | 14 (41.2) |
Nausea | 22 (33.8) | 8 (23.5) |
Fatigue | 16 (24.6) | 10 (29.4) |
Neutropenia | 14 (21.5) | 9 (26.5) |
Anemia | 9 (13.8) | 9 (26.5) |
Vomiting | 14 (21.5) | 3 (8.8) |
Decreased appetite | 12 (18.5) | 3 (8.8) |
Diarrhea | 11 (16.9) | 3 (8.8) |
Pyrexia | 9 (13.8) | 5 (14.7) |
Asthenia | 7 (10.8) | 5 (14.7) |
Constipation | 9 (13.8) | 3 (8.8) |
Leukopenia | 7 (10.8) | 5 (14.7) |
Stomatitis | 10 (15.4) | 1 (2.9) |
Alopecia | 6 (9.2) | 4 (11.8) |
Oedema peripheral | 7 (10.8) | 2 (5.9) |